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Over 100 mutations in Cu/Zn-superoxide dismutase (SOD1)
result in familial amyotrophic lateral sclerosis. Dimer dissocia-
tion is the first step in SOD1 aggregation, and studies suggest
nearly every amino acid residue in SOD1 is dynamically con-
nected to the dimer interface. Post-translational modifications
of SOD1 residues might be expected to have similar effects to
mutations, but fewmodifications have been identified. Here we
show, using SOD1 isolated from human erythrocytes, that
human SOD1 is phosphorylated at threonine 2 and glutathiony-
lated at cysteine 111. A second SOD1 phosphorylation was
observed and mapped to either Thr-58 or Ser-59. Cysteine 111
glutathionylation promotes SOD1 monomer formation, a nec-
essary initiating step in SOD1 aggregation, by causing a 2-fold
increase in theKd. This change in the dimer stability is expected
to result in a 67% increase in monomer concentration, 315 nM
rather than 212 nM at physiological SOD1 concentrations.
Because protein glutathionylation is associated with redox reg-
ulation, our finding that glutathionylation promotes SOD1
monomer formation supports a model in which increased oxi-
dative stress promotes SOD1 aggregation.
Familial amyotrophic lateral sclerosis (FALS)4 is the heredi-
tary form of amyotrophic lateral sclerosis, a fatal disease char-
acterized by progressive motor neuron loss (1). A subset of
FALS is caused by mutations in the gene encoding
homodimeric Cu/Zn-superoxide dismutase (SOD1), which
forms intraneuronal aggregates (2). Although SOD1 aggrega-
tion is involved in SOD1-mediated FALS, it is generally
believed that the functional properties of the enzyme are not
related to the toxic gain of function imparted by mutations in
SOD1 (3). However, the discovery of roles for SOD1 in the
regulation of the cellular phosphorylation balance (4) and redox
state (5) provides additional avenues for connecting the cellular
role of SOD1 to FALS. The classical studies of SOD1 were gen-
erally performed using bovine erythrocyte SOD1 or recombi-
nant human SOD1. Although recombinant methods are widely
used to produce SOD1 mutants, a disadvantage of studying
recombinant SOD1 is the absence of potentially important
post-translational modifications present in human tissues. The
initial SOD1 crystal structure was solved using bovine erythro-
cyte SOD1 (6) and no structure of human erythrocyte SOD1 is
available. Here we report results using human erythrocyte
SOD1 rather than the recombinant enzyme and find that the
native enzyme features a consistent pattern of post-transla-
tional modifications. Using a combination of “bottom-up” and
“top-down”mass spectrometry (MS) approaches, we show that
SOD1 isolated from human erythrocytes is post-translationally
phosphorylated and glutathionylated. These modifications
occur near the SOD1 dimer interface. Because monomer for-
mation is thought to be the first intermediate leading to SOD1
aggregation (7, 8), we tested the dimer stability of modified
SOD1 found, as expected, that glutathionylation promotes the
formation of SOD1 monomer.
EXPERIMENTAL PROCEDURES
Isolation of hSOD1 from Erythrocytes—Expired human
erythrocytes were obtained from the University of North Caro-
lin-Chapel Hill Hospital blood bank. Human erythrocytes were
preserved using one of several anticoagulants: AS-1, AS-3, or
AS-5 (stored as long as 42 days before expiration). Bovine eryth-
rocytes preserved with 0.38% sodium citrate were purchased
from Pel-Freez Biologicals, Rogers, AR. SOD1 was isolated
from human erythrocytes using a modification of the protocol
originally used byMcCord andFridovich (9). Following acetone
precipitation of SOD1, we dialyzed SOD1 against 20 mM Tris,
pH 7.8, and performed hydrophobic interaction chromatogra-
phy and anion exchange chromatography using an AKTA-
FPLC to remove trace impurities. For hydrophobic interaction
chromatography, dry (NH4)2SO4 was added to bring the final
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concentration to 55%. The protein was loaded onto a HiTrap
phenyl-Sepharose column (GE Healthcare) and eluted with a
gradient from 2 to 0 M (NH4)2SO4 in 20 mM Tris, pH 7.8. Frac-
tions containing SOD1 were combined and dialyzed against
salt-free 20 mM Tris, pH 7.8, and anion exchange chromatog-
raphy was performed using a MonoQ column (GE Healthcare)
with a gradient from 0 to 1 M NaCl in 20 mM Tris, pH 7.8. The
fractions containing SOD1 were dialyzed against 20 mM Tris,
150 mM NaCl, pH 7.8, and concentrated.
Isolation of hSOD1 from Saccharomyces cerevisiae—Human
wild type SOD1 was expressed using plasmid yEP351-hwt-
SOD1 in the EG118 SOD1-knock out yeast strain (both kindly
provided by J. S. Valentine). Growthwas carried out at 30 °C for
72 h in YPD media. We uses a modified isolation protocol
adapted from Goscin and Fridovich (10) where we replaced all
steps, after stirring the lysate at room temperature, with high
speed centrifugation and dialysis of the supernatant against 20
mM Tris, pH 7.8, to remove the chloroform and ethanol. Trace
impurities were removed by MonoQ and phenyl-Sepharose
chromatography as described above.
Remetallation of hSOD1 from yeast was performed by suc-
cessive dialysis at 4 °C against: (a) 50 mM acetate, pH 3.5, 150
mM NaCl, 10 mM EDTA; (b) 50 mM acetate, pH 3.5, 150 mM
NaCl; (c) 50mM acetate, pH 3.5, 150mMNaClCuSO4 (5-fold
molar excess compared with [SOD1]); (d) 20 mM Tris, pH 7.8,
150 mM NaCl  ZnCl2 (5-fold molar excess compared with
[SOD1]); and (e) 20 mM Tris, pH 7.8, 150 mMNaCl. Upon con-
centration with a YM-10 ultrafiltration membrane (Millipore,
Bedford,MA), a blue-green colorationwas observed, indicating
incorporation of copper into the enzyme.
Microcapillary () ESI-FT-ICR-MS Analysis (Top-down
Approach)—MS spectra are acquired using a hybrid Qe-Fou-
rier Transform IonCyclotron Resonance (FT-ICR)-Mass Spec-
trometer, equipped with a 12.0-tesla actively shielded magnet
(Apex Qe-FTICR-MS, 12.0 T AS, Bruker Daltonics, Billerica,
MA), and an Apollo II microelectrospray source. The voltages
on the ESI sprayer, interface plate, heated capillary exit,
deflector, ion funnel, and skimmer were set at 4.3 kV, 3.9 kV,
300 V, 250 V, 175 V, and 80 V, respectively. The temperature of
the ESI source was maintained at 180 °C. Desolvation was
carried out using a nebulization gas flow (2.0 bar) and a coun-
tercurrent drying gas flow (4.0 liters/s). The electron capture
dissociation (ECD) hollow dispenser cathode was heated to
increase the temperature inside the ICR cell above 180 °C with-
out application of ECD bias, eliminating non-covalent adducts.
SOD1 sample solutions were directly infused using a syringe
pump (Harvard Apparatus, Holliston, MA) and a 250-l
syringe (Hamilton, Reno, NV), and electrosprayed at an infu-
sion flow rate of 90 l/h. Before transfer, ion packets are accu-
mulated inside the collision cell for a duration of 0.2 s. 50 MS
scans per spectrumwere acquired in the ICR cell with a resolu-
tion of 580,000 atm/z 400.
MS/MS Fragmentation for Sequencing Full-length Proteins—
FT-MS/MS spectra were obtained from collision-induced dis-
sociation (CID) performed with in-source collision-activated
dissociation followed by collision cell-activated dissociation, or
from ECD. In CID experiments, argon was used as the collision
gas (PAr  1.6  106 torr). Precursor ions were isolated with
Q1 (Mass SelectiveQuadrupole) and subjected to collision cell-
activated dissociation using an isolation window width of 5 Da.
50MS/MS scans were acquired in the ICR cell with a resolution
of 580,000 atm/z 400. In ECDexperiments, precursor ionswere
isolated with Q1 and subjected to ICR cell. Isolation window
width was 10 Da. Low energy electrons were generated by a
heated hollow dispenser cathode with a bias voltage of 1.5 V.
ECD lens voltage was set at 15.0 V. The electrons produced by
the hollow cathode were pulsed into the ICR cell with a pulse
length of 0.0050 s, causing fragmentation of the ions that were
already trapped in the ICR cell. Tomaximize the ion population
before irradiation, the cell was filled with 5 iterations of ion
accumulation from the external collision cell of the isolated
precursor as suggested (11). In bothCID and ECDexperiments,
50 MS/MS scans per spectrum were acquired in the ICR cell
with a resolution of 580,000 atm/z 400.
Tempo LC MALDI Fractionation and MALDI-TOF-TOF
Analysis (Bottom-up Approach)—SOD1 protein samples were
digested with trypsin (Promega, Madison, WI) overnight at
37 °C in an enzyme to substrate ratio of 1:40 by mass. After
desalting with ZipTipC18 (Millipore), 0.5 l of the tryptic
digests were directly spotted on a 384-well stainless steel
matrix-assisted laser desorption/ionization (MALDI) target
plate for pre-scan using a MALDI time-of-flight/time-of-flight
(TOF/TOF) tandem mass spectrometer (ABI 4800 Proteomics
Analyzer, Applied Biosystems, Foster City, CA). In an analytical
run the peptide digests were further separated using a reverse
phase liquid chromatography (LC) system (Tempo LCMALDI,
Applied Biosystems, Foster City, CA). 10 l of tryptic peptides
were injected and directly loaded on a C18 capillary column
(Monolithic silica RP C18 endcapped, 100 m inner diameter,
15 cm length, Chromolith CapRod, Merck KGaA, Darms-
tadt, Germany) with a loading buffer (H2O/acetonitrile/triflu-
oroacetic acid, 98/2/0.1, v/v/v), and separated using a gradient
from 100% A (H2O/acetonitrile/trifluoroacetic acid, 98/2/0.1,
v/v/v) to 40% B (H2O/acetonitrile/trifluoroacetic acid, 2/98/
0.1, v/v/v) over 70 min, and 40–80% B in 10 min, at a flow rate
of 1.0 l/min. The column eluates are mixed with a matrix
solution of 7.0 mg/ml re-crystallized -cyano-4-hydroxycin-
namic acid (Sigma) in H2O/acetonitrile, 30/70 (v/v), and 5 mM
ammonium citrate, deposited on a 2000-well stainless steel
MALDI target plate at a frequency of 0.15 Hz, and analyzed by
ABI 4800 MALDI TOF/TOF (200 Hz Nd:YAG laser,
OptiBeamTM). Each spot was analyzed inMSmode in themass
range of 800–4000 Da, by accumulating ion signals over 1200
laser shots. Up to 15 ions with a signal-to-noise ratio less than
30 were selected for MS/MS analysis, which was performed
with a1.0 kV collision energy and 1.0 106 torr collision gas
(air) pressure. Acquisition of an MS/MS spectrum was inter-
rupted when 2000 laser shots (40 sub-spectra from 50 laser
shots each) were accumulated. Mass calibration was applied by
spotting the standard peptide mixture at six places around the
target plate (12). Acquired MS and MS/MS spectra were
searched using Mascot 2.2 (Matrix Science, London, UK)
embedded in GPS 3.5 (Applied Biosystems).
Phosphatase Treatment of SOD1—To prepare dephospho-
rylated. SOD1 we use agarose-linked alkaline phosphatase
(Sigma). The beads were washed using 20 mM Tris, 150 mM
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NaCl, pH 7.8, buffer and added to a solution of SOD1 at a 1:200
(v/v) ratio. The reaction was performed overnight at 37 °C.
Size Exclusion Chromatography—Size exclusion chromatog-
raphy was carried out using a Superdex 200 10/300 column
(GE) and a 200-l injection loop. The void volume of the col-
umn was 8 ml and a flow rate of 0.5 ml/min was used at 4 °C.
For measurement of the dimer dissociation constant, Kd, sam-
ples of SOD1 at pH 7.8 were diluted to 1.25 nM to facilitate
dimer dissociation using the column running buffer (20 mM
Tris, pH 7.8, 150 mM NaCl, and 10 g/liter bovine serum albu-
min to prevent SOD1 adherence to the column and the glass
collection tubes). Samples are incubated at 37 °C for up to 5 h to
ensure proper equilibration. 250-l fractions were collected
throughout the chromatography experiment for use in immu-
noblotting. Fractions were acetone precipitated by the addition
of 4 volumes of cold acetone to the sample and a 1-h incubation
at 20 °C. The samples are pelleted for 30 min at 20,000 rpm.
The precipitated SOD1 was resuspended in protein solvent
containing sodium dodecyl sulfate and -mercaptoethanol and
resolved by polyacrylamide gel electrophoresis. Following
transfer to a polyvinylidene fluoride membrane and blocking
with 5% bovine serum albumin, blots were probed with a sheep
anti-SOD1 primary antibody (Calbiochem number 574597)
and a rabbit anti-sheep alkaline phosphatase-conjugated sec-
ondary antibody (Thermo Scientific number 31360). The blots
are incubated in ECF reagent (Amersham Biosciences) and
visualized using a GE Healthcare STORM 840 Phosphor-
Imager. Quantification of band intensities is performed using
the ImageQuant software (GE Healthcare).
Kd Determination Using SOD1 Activity—We tested for a
reduction in the rate of 6-hydroxydopamine autoxidation as
previously described (13). The assaywas sufficiently sensitive to
allow measurement of SOD1 concentrations as low as 100 pM.
The activity of glutathionylated and
non-glutathionylated 2.5 nM SOD1
wasmeasured before and after a 3-h
equilibration at 37 °C. Activity
assays performed after 3 and 5 h
incubation at 37 °C show no addi-
tional loss in activity, indicating that
the monomer-dimer equilibrium
was reached at 3 h. The percent
dimer dissociation at equilibrium
was determined using the following
equation,
% Dimer dissociation
 % activity loss  1  vC  vEvC  vI
where vc is the initial rate of the con-
trol reaction, vE is the initial rate of
the reaction containing equilibrated
SOD1, and vI is the initial rate of the
reaction measured immediately
upon dilution of SOD1 from a con-
centrated stock solution. Assuming
a physiological SOD1 concentration
of 40 M (14), we calculated themonomer concentration based
on theKd. For aKd of 2.25 nM, we expect themonomer concen-
tration to be 212 nM. For a Kd of 5 nM, we expect a monomer
concentration of 315 nM, a 67% increase.
RESULTS
SOD1 Is Modified in Human Erythrocytes—Using a 12-tesla
FT-ICR-MS with ultrahigh mass accuracy and resolution, full-
length wild-type SOD1 from human erythrocytes was found to
have a monoisotopic mass of 15837.8902 Da (Fig. 1A), corre-
sponding to the theoretical mass of 15837.8812 Da for N-ter-
minal acetylated wild-type human SOD1. In addition to the
acetylated form, two strong peaks with masses of 15935.8702
and 16033.8462 Da corresponding to the respective addition of
one (98 Da) or two (196 Da) hydrated phosphate groups
were observed, as well as a third peak corresponding to the
modification of SOD1 by glutathione (305 Da). The protein
was treated with alkaline phosphatase, which resulted in the
loss of the 98 and 196 Da peaks (Fig. 1c), suggesting both
sites are related to phosphorylation.
To differentiate between the non-covalent association of
H3PO4 or H2SO4 and a hydrated phosphate ester, both
expected to result in the addition of98 Da, we heated the ICR
cell to above 180 °C. Heating results in the conversion of 98
and 196 Da peaks to 80 and 178 Da, respectively, but has
no effect on the 305-Da shift (Fig. 1B). The CID/ECD spectra
of the 80-Da peak (supplemental Fig. S1), which imply phos-
phorylation at threonine 2 (Thr-2) (Fig. 2B), are similar to those
of the 98-Da peak (supplemental Fig. S2), indicating that the
98-Da peak belongs to single phosphorylation plus one water
molecule. Similarly, the CID/ECD spectra of the178-Da peak
indicates that it possibly arises from double phosphorylation
plus one water molecule (supplemental Fig. S4). A 160-Da
FIGURE 1. Post-translational modification of SOD1. ESI-FTICR-MS spectra of: A, human SOD1 isolated from
erythrocytes; B, high temperature spectrum of human erythrocyte SOD1 causing phosphorylation peaks to
shift from 98 to 80 Da; and C, alkaline phosphatase-treated human SOD1 isolated from erythrocytes. D, a UV
trace from anion exchange separation of three populations of human erythrocyte SOD1, the unlabeled peak is
composed of impurities. E, a comparison of the ESI-FTICR-MS spectra for populations 1–3 from panel D
showing SOD1 enrichment of glutathionylation in population 3. Phosphorylation is indicated by solid vertical
arrows. Glutathionylation is indicated by the dashed arrow.
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peak corresponding to double phosphorylation was only
observed in SOD1 extracted from freshly drawn human eryth-
rocytes (supplemental Fig. S9). However, the signal intensities
of the 160, 178, and 196 Da peaks were insufficient for
FT-ECD fragmentation experiments in mapping the second
modification site.
We found that human erythrocyte SOD1 is phosphorylated
at Thr-2 (Fig. 2B, supplemental Figs. S1 and S2), but due to
difficulty in sequencing doubly phosphorylated SOD1, even
after the enrichment of phosphorylated protein, we can only
report that a second phosphorylation is possibly located at
either Thr-58 or Ser-59 (supplemental Fig. S4). Residues 58 and
59 are located in the zinc loop in SOD1, which both chelates the
zinc atomat the active site and accounts for several dimer inter-
face contacts.
The site of glutathionylation in human SOD1 was deter-
mined by analyzing tryptic digestions of human erythrocyte
SOD1 with Tempo LC-MALDI fractionation and MALDI-
TOF-TOF. The acquired MS and MS/MS spectra were
searched using Mascot 2.2 embedded in GPS 3.5. In 13 unique
SOD1 peptides, we found mass shifts of 305 Da from C-ter-
minal ions y5 to y20 relative to the MS/MS spectra of the
unmodified peptides (supplemental Fig. S3), which indicates
that cysteine 111 (Cys-111) is susceptible to glutathionylation.
Peptides containing cysteines 6, 57, and 146 were found not to
be glutathionylated (supplemental Fig. S5).
Human erythrocyte SOD1 was separated into multiple
charge populations by anion exchange chromatography (Fig.
1D). Each population shows distinct modification patterns in
itsmass spectrum (Fig. 1E). The SOD1 that elutes at the highest
ionic strength, population 3 (Fig. 1, D and E), has a dominant
peak atm/z  16142.9600 Da, corresponding to the acetylated
protein derivatizedwith glutathione. The extent of phosphoryl-
ation varies in SOD1 populations 1 and 2 that elute at low and
medium salt concentrations (Fig. 1,
D and E). A pool of SOD1 that is
simultaneously phosphorylated and
glutathionylated was also observed
(Fig. 1E).
Distribution of Modifications in
Individual Erythrocyte Samples—
The modifications described above
were observed in SOD1 isolated
fromerythrocytes pooled frommul-
tiple donors and as such, any modi-
fications could have arisen due pri-
marily to contributions from a
single donor. To investigate the
consistency of glutathionylation
and phosphorylation levels between
individuals, we next compared
SOD1 from individual samples of
human erythrocytes. Of six individ-
ual samples, five contained both
phosphorylation and glutathionyla-
tion (Table 1). One sample lacked
glutathione but was significantly
phosphorylated. Assuming inde-
pendent probabilities of phospho-
rylation and glutathionylation of
FIGURE 2. Location of SOD1 modifications in human erythrocytes. A, the SOD1 homodimer (Protein Data
bank code 2V0A) with glutathionylated Cys-111 and phosphorylated Thr-2 modeled using PYMOL. B, the SOD1
dimer interface showing the relative positions of the phosphate and glutathione moieties. C, a ESI-FTICR-MS-
CID MS/MS spectrum with the phosphorylation at Thr-2 for a representative b-ion illustrated. A complete
MS/MS spectrum is shown in supplemental Fig. S1. D, a Tempo LC-MALDI-TOF-TOF MS/MS spectrum with
several fragment ions from the parent peptide 92DGVADVSIEDSVISLSGDHCIIGR115 highlighted, which are
shifted by glutathionylation. Complete MS/MS spectra are shown in supplemental Figs. S3 and S4.
TABLE 1
Comparison of modifications in independent erythrocyte samples
SOD1 isolated from individual samples of human erythrocytes are analyzed by ESI-FTICR-MS without separation of modification states. We calculate the frequencies of
phosphorylation (fP), glutathionylation (fG), and both (fPG) from the percentages of each modified SOD1 species in the sample as follows: fP  (%P  %PG)/100; fG 
(%G  PG)/100; and fPG  %PG/100. Assuming that phosphorylation and glutathionylation are independent processes, we expect the frequency of simultaneous
phosphorylation and glutathionylation to be fP  fG  fPG. The sample blood types are as follows: 1 is AB, 2 is AB, 3–5 are O, and 6 is O.
Sample No. Unmodified SOD1 Phosphorylated SOD1 Glutathionylated SOD1 Both
1 51.1  11% 8.5  1.8% 18.8  3.9% 21.7  4.6%
fP  0.30  0.05 fG  0.41  0.06 Expected  12  4%
2 36.9  2.9% 6.6  1.3% 34.0  3.6% 22.6  0.3%
fP  0.29  0.01 fG  0.57  0.05 Expected  16.5  1.6%
3 41.1  5.0% 14.4  4.4% 25.8  1.5% 18.7  1.6%
fP  0.33  0.05 fG  0.45  0.02 Expected  14.7  2.3%
4 53.6  0.7% 22.5  4% 17.1  3.6% 12.2  1.0%
fP  0.35  0.04 fG  0.29  0.04 Expected  10.2  1.8%
5 45.2  3.0% 14.6  0.5% 31.5  3.1% 12.0  0.3%
fP  0.27  0.01 fG  0.44  0.03 Expected  11.6  0.9%
6 54.4  11.4% 45.6  9.6% None None
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SOD1, we expect the probability of observing both modifica-
tions to be the product of the individual frequencies. In eryth-
rocyte samples 1–3, the calculated frequency of combined
phosphorylation and glutathionylation is significantly smaller
than the measured frequency, suggesting that phosphorylation
and glutathionylation are co-dependent in the case of SOD1.
However, the observed frequency of combined modification in
samples 4 and 5 is only marginally higher than the expected
frequency and is within the experimental error. This behavior
may arise from differences in phosphatase activity among indi-
viduals, or other variables not controlled for in this study.
Modifications in Freshly Drawn Human Erythrocytes—The
phosphorylation and glutathionylation of human erythrocyte
SOD1does not occur as a result of long-termblood storage.We
isolated SOD1 from human erythrocytes immediately follow-
ing their collection from two donors. The results are summa-
rized in Table 2. Mass spectra from each donor (ages 37 and 73
years) included major peaks related to both SOD1 phosphoryl-
ation and glutathionylation. In addition, we observed peaks
related to oxidized SOD1. These peaks were shifted 16 and
32 Da from the unmodifiedmass of SOD1 (supplemental Fig.
S9). Because there are no 16 or 32 Da shifted peaks relative
to either phosphorylated or glutathionylated SOD1, we postu-
late that Cys-111 is the site of the oxidation, as has been
observed in vitro (15). Alternatively, histidine residues in SOD1
might be oxidized because SOD1 lacksmethionine and the oxi-
dation of histidine residues in SOD1 has been observed previ-
ously (16). It is interesting to note the abundance of oxidized
SOD1 species in sample B compared with sample A given that
the more highly oxidized sample was drawn from a 73-year-old
donor, whereas sample A was drawn from a 37-year-old donor.
However, a comparison based on only two samples is insuffi-
cient to support a hypothesis that the difference is related to
age.
Species/System Effects on Modifications—Because S. cerevi-
siae contain a copper chaperone for SOD1, it is widely used for
expressing recombinant human SOD1, but do phosphorylation
and glutathionylation of human SOD1 occur in yeast or other
systems used to isolate SOD1? To answer this question, we
purified and analyzed recombinant SOD1 from yeast, as well as
endogenous SOD1 from both yeast and bovine erythrocytes.
Mass spectra of human SOD1 isolated from S. cerevisiae indi-
cate an exact match with the acetylated, unmodified SOD1
found in human erythrocytes (supplemental Fig. S8). We sepa-
rated a sample of yeast-expressed human SOD1 into subpopu-
lations of high and low negative net charge and found similar
mass shifts in the deconvoluted mass spectra indicating SOD1
glutathionylation but not phosphorylation (supplemental Fig.
S8). Themass spectrum of SOD1 isolated from bovine erythro-
cytes using the identical protocol used for human erythrocytes
indicates bovine SOD is neither phosphorylated nor glutathio-
nylated, nor is endogenous yeast SOD1 (supplemental Figs. S6
and S7, respectively), an expected result given that neither spe-
cies has a cysteine at position 111 in SOD1. Cysteine 6 is con-
served between bovine and human SOD1 but we find no gluta-
thionylation of this residue in either species. We hypothesize
that SOD1 phosphorylationwas not previously observed due to
the common use of bovine erythrocyte SOD1 or recombinant
human SOD1.
Effect of Modifications on SOD1 Dimer Dissociation—Thr-2
appears to be at a sufficient distance so as not to participate
directly in the SOD1 dimer interface. However, phosphoryla-
tion can change both the structure and dynamics of proteins
(17) and thus, the distance from the interface and the active site
does not preclude Thr-2 phosphorylation from altering the sta-
bility or activity of SOD1. Cys-111 residues in each SOD1mon-
omer are directly apposed in a cleft at the dimer interface. We
postulated that the addition of the glutathione tripeptide to
Cys-111 will result in a measurable decrease in SOD1 dimer
stability. Because of the proximity of both Thr-2 phosphoryla-
tion and Cys-111 glutathionylation to the dimer interface and
evidence that dimer stability is important for preventing SOD1
aggregation (18, 19), we measured the effect of glutathionyla-
tion and phosphorylation on the in vitro stability of dimeric
SOD1.
Using size exclusion chromatography, we compared SOD1
species separated by anion exchange as described above (peaks
1 and 3 in Fig. 1E). Altered dimer stability of SOD1 in peak 3
relative to peak 1 is expected to be the result of Cys-111 gluta-
thionylation because substoichiometric amounts of phospho-
rylation are present in both SOD1 species. Due to the unusually
high stability of the SOD1 dimer (the dissociation constant of
human SOD1 isolated from yeast is less than 10 nM (20)), it was
necessary to perform the experiment at low concentrations. To
observe dissociation into monomers, we performed size exclu-
sion chromatography using 1.25 nM SOD1. We compared
SOD1 with and without glutathionylation and found that glu-
tathionylation has a marked destabilizing effect on the SOD1
dimer. Progressive SOD1 dimer dissociation was observed
upon incubation at 37 °C for up to 5 h. We observed a 3-fold
increase in monomer formation in glutathionylated SOD1 rel-
ative to SOD1 unmodified by glutathione (Fig. 3).
KdDetermination Using an Assay for SOD1Activity—Mono-
meric SOD1 was postulated to have reduced activity based on
findings thatmutations forcingmonomeric SOD1 show an 80%
activity loss (21). We therefore postulated that activity loss can
TABLE 2
Comparison of modifications in freshly drawn single erythrocyte samples
SOD1 isolated immediately after removal from donors and analyzed by ESI-FTICR-MS. Donor age is listed under the sampe I.D. All frequencies calculated as described
in Table I. The percentage of unmodified SOD1 is calculated using the sum of the intensities of SOD1 peaks, which are neither phosphorylated nor glutathionylated (i.e.
oxidized SOD1 species are considered unmodified).
Sample I.D. Unmodified SOD1 Phosphorylated SOD1 Glutathionylated SOD1 Both
A: age 37 38.6  5.8% 13.3  2.0%
fP  0.23  0.03
38  5.7%
fG  0.48  0.06
10.1  1.5%
Expected  11.3  2.0%
B: age 73 37.4  5.6% 8.4  1.3%
fP  0.22  0.02
40.8  6.1%
fG  0.54  0.06
13.4  2.0%
Expected  11.%  1.7%
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be used as an indicator of dimer dissociation upon dilution
fromhigh concentrations inmeasuring theKd of SOD1. TheKd
is important considering that concentration of the SOD1 spe-
cies nucleating aggregation depends upon the nth power of the
monomer concentration, where n is the number of monomers
in the nucleating species. Small increases in the Kd, therefore,
result in large increases in the number of nuclei, especially as
the number of monomers in the nucleus increases. Using a
spectrophotometric assay sufficiently sensitive to assay sub-
nanomolar concentrations SOD1, we measured the reduction
in the reaction rate in the presence
of 2.5 nM SOD1 at equilibrium (3 h),
normalized to the activity immedi-
ately after dilution (Fig. 4). We
observed a loss in SOD1 activity
concomitant with dimer dissocia-
tion, evident as a reduction in the
initial reaction rate relative to
the control reaction. We tested the
effect of glutathionylation on dimer
stability by comparing SOD1 spe-
cies separated by anion exchange as
described above (peaks 1 and 3 in
Fig. 1E). Although the initial reac-
tion rate was similar (2  104
absorbance units s1), the gluta-
thionylated SOD1 showed a higher
rate at equilibrium, indicating less
SOD1 activity and therefore, more
dimer dissociation. Based on the
percent reduction in activity, we
estimated the Kd to be 2.25 nM for




of Native Human SOD1—Here we
report that SOD1 can be phospho-
rylated at Thr-2 and at either
Thr-58 or Ser-59. We also confirm
previous findings of SOD1 gluta-
thionylation and map that modifi-
cation to Cys-111. Previously in our
laboratory, a series of molecular
dynamics simulations was carried
out that showed that residues in
every region of SOD1 show high
connectivity to the dimer interface
(22) and that residues closely associ-
ated with its stability reside on the
surface of SOD1 (23). Other recent
findings suggest that loss of copper
and zinc at the metal binding site
results in structural fluctuation at
the dimer interface (24), providing
further rationale for diverse pertur-
bations resulting in SOD1 aggrega-
tion via dimer destabilization. In light of these findings, we pos-
tulated that post-translational modifications, like point
mutations, would have a similar effect on the structure and
dynamics of SOD1. To test the effect of post-translationalmod-
ifications on the enzyme, we separated a sample of SOD1 into a
population that contained a low percentage of phosphorylation
and a population that was very highly glutathionylated while
also phosphorylated to a similar degree as the non-glutathiony-
lated enzyme.We found that these two forms of SOD1 differ in
their propensity toward forming monomers, the glutathiony-
FIGURE 3. SOD1 dimer is destabilized by glutathionylation. Non-glutathionylated (SOD1) and glutathiony-
lated (GS-SOD1) SOD1 diluted to 1.25 nM is allowed to equilibrate at 37 °C and resolved by size exclusion
chromatography to monitor dimer dissociation. Glutathionylated SOD1 dissociates into monomer upon incu-
bation at low concentrations, whereas non-glutathionylated SOD1 begins to dissociate only slightly after 5 h at
37 °C. Inset, Western blots of 1.25 nM size exclusion chromatography fractions are aligned above a size exclusion
chromatograph of 30 M GS-SOD1 dimer to illustrate the dissociation of GS-SOD at low concentration.
FIGURE 4. Measurement of dimer dissociation using an assay for SOD1 activity. An activity assay compar-
ing glutathionylated SOD1 (GS-SOD1) to unmodified SOD1 (SOD1) at 2.5 nM. The % activity change due to
dimer dissociation was estimated by assaying samples of SOD1 after a 3-h equilibration at 37 °C (dashed lines)
and normalizing against non-equilibrated samples (solid lines). A control reaction containing only 6-hydroxy-
dopamine in sample buffer is shown in solid blue.
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lated SOD1 formingmonomermore readily.Our previous find-
ing thatmonomeric SOD1 is the first intermediate formed dur-
ing SOD1 aggregation suggests that glutathionylation, which
has a destabilizing effect on the SOD1 dimer, may affect the
initiation of SOD1 aggregation in FALS.
Glutathionylation has been reported several times in eryth-
rocyte SOD1, including erythrocytes collected from FALS
patients (25, 26), and treatment of apo-SOD1withGSSGcauses
aggregation in vitro (27). We show here that only Cys-111 glu-
tathionylation is present in vivo.However, glutathionylation of
SOD1 has also been performed in vitro and shown to modify
each of the four cysteines (27). The involvement of Cys-111
disulfide bonding during SOD1 aggregation has been suggested
(28). However, bovine SOD1 lacks Cys-111, yet is capable of
aggregating (7). Therefore, Cys-111 glutathionylation need not
interferewith SOD1 aggregation by blocking a specific disulfide
bond in the aggregated state.
Oxidation of SOD1 in Freshly Drawn Human Erythrocytes—
We observe SOD1 oxidation, in addition to phosphorylation
and glutathionylation, in freshly drawn human erythrocytes.
Although the sample number is not sufficient to show a rela-
tionship between age and the degree of SOD1 oxidation, the
two samples show differences in this property. Erythrocytes are
short-lived cells and have an average lifespan of 120 days in
humans. Therefore, the SOD1 used in our experiments was
isolated from both young and old cells. Because virtually all of
the unmodified SOD1 in one of the samples was oxidized, we
conclude that differences in SOD1 oxidation levels are not the
result of a cumulative process wherein a population of SOD1 is
slowly modified as each individual erythrocyte “ages,” but
rather an instantaneous process in which the population of
SOD1 responds to differences in the individuals that may or
may not be age-related, such as oxidizing conditions in eryth-
rocytes or the surrounding plasma.
Modification Differences in Different Systems—When study-
ing the effects of mutations on SOD1, it is important to have a
proper benchmark for SOD1 as it exists inside human tissues. It
is clear from our comparison of human SOD1 isolated from
both human erythrocytes and yeast that the latter model for
native SOD1 lacks at least one feature of native SOD1, phos-
phorylation. Because we studied wild type SOD1 isolated from
human tissue, we believe that phosphorylation and glutathio-
nylation are features of the SOD1native state and not a result of
a disease-related process. However, analysis of spinal cord tis-
sue from sporadic amyotrophic lateral sclerosis patients
revealed many kinases that are up-regulated and found dra-
matic differences in the phosphorylation of multiple proteins
(29), suggesting that changes in SOD1phosphorylation are pos-
sible in FALS.
Possible Regulatory Role of SOD1—Phosphorylation and glu-
tathionylation may impact the function of SOD1 through the
mediation of interactionswith other proteins. SOD1 is involved
in cellular redox regulation through a direct interaction with
the Rac1-NOX2 enzyme complex (5). This example of a physi-
cal interaction between SOD1 and a functional enzyme com-
plex illustrates onemechanism throughwhich phosphorylation
and/or glutathionylation of SOD1 could play a significant role
without altering its traditionally recognized activity as a free
radical scavenger.
Glutathione plays a key role in establishing the redox state of
the cell (30). The high ratio of reduced (GSH) to oxidized
(GSSG) glutathione is tightly controlled by both glutathione
reductase, which usesNADPH to reduceGSSG toGSH, and the
active removal of GSSG from the cytosol (31). During scenarios
of oxidative stress, the concentration of GSSG increases dra-
matically (32) and reversibly glutathionylates free cysteines in
what is thought to be a general protective mechanism against
permanent oxidation of proteins by reactive oxygen or nitrogen
species (33). In addition to its general role, several examples
of specific functional roles for protein glutathionylation are
documented (34–37). Recent evidence also suggests that
SOD1 may be involved in growth factor signaling through
the production of H2O2, which acts as a second messenger in
modulating the activity of protein-tyrosine phosphatases
and thus, the balance of phosphorylation in the cell (4). Pred-
icated on these findings, we present a model for the impact of
SOD1 modification on oxidative protein-tyrosine phospha-
tase regulation (Fig. 5).
SOD1 glutathionylation increases dimer dissociation, facili-
tating aggregation in the presence of contributing factors such
as oxidative damage or destabilizing FALS mutations. Even a
modest effect of glutathionylation on SOD1 dimer dissociation,
combined with the effects of mutations, could affect FALS-re-
lated aggregation over time. Furthermore, a SOD1 variant engi-
neered to bemonomeric retains only 20% activity relative to the
wild type dimer (21), and therefore we postulate that glutathio-
nylation, by inducing dimer dissociation, inhibits SOD1 activity
(Fig. 5).
Decreased Dimer Stability: Possible Implications for FALS—
The link between SOD1 mutations, protein aggregation, and
FALS is not fully understood, but there are multiple reports
showing that dimer dissociation is an early event during SOD1
aggregation (7, 8). Our finding that modifications can facilitate
SOD1 dimer dissociation suggests a possible link between the
FIGURE 5. Model for the participation of SOD1 in protein-tyrosine
phosphatase (PTP) redox regulation. SOD1 interacts with redox regula-
tion of phosphatase activity through its conversion of superoxide (O2
. ) to
hydrogen peroxide (H2O2). Glutathione reduces the activity of SOD1 (red
dashed line) by facilitating monomer formation. SOD1 monomer forma-
tion is also associated with aggregation, and ribbon structures are used to
show the proposed destabilizing effect on the SOD1 dimer as a result of
Cys-111 glutathionylation.
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normal characteristics of SOD1 and its role in FALS. Although
relatively modest, a 2-fold increase in Kd resulting from SOD1
modification translates to nearly a 70% increase in SOD1mon-
omer concentration. Because nucleation of SOD1 aggregation
is dependent on at least the square of the monomer concentra-
tion, we expect a 70% increase in monomer concentration to
have amarked effect on the nucleation of SOD1 aggregates. For
example, the formation of a hypothetical nucleus made up of 3
glutathionylated SOD1 monomers becomes roughly 5 times
more likely and a nucleus of 6 monomers 24 times more likely
relative to unmodified SOD1.
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